Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Glioblastoma Multiforme Treatment Market: By Drug Type, By Distribution Channel and Geography
Glioblastoma Multiforme Treatment Market: By Drug Type, By Distribution Channel and Geography
Glioblastoma multiforme treatment market size was valued at US$ 2.85 billion in 2023 and is poised to grow at a CAGR of 9.9% from 2024-2030. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of the central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. The glioblastoma multiforme is diagnosed by using the imaging modules namely, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT). Glioblastoma multiforme is classified into two types namely, gliosarcoma and giant cell glioblastoma. Gliomas are tumors that emerge from glial cells and might occur in the brain or the spinal cord. The common symptoms observed in patients suffering from glioblastoma multiforme include nausea, headache, seizure, memory loss, and hemiparesis, among others.
The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global market. Furthermore, an increase in research and development in gene therapy, molecular biotechnology for the treatment of CNS-associated disorders, urgent need for alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma multiforme treatment over the forecast period. However, major restraints of the glioblastoma multiforme treatment are current treatment therapies such as radiation and chemotherapy do not prevent tumor recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the market growth over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
9.9%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in prevalence of brain tumours (According to U.S. National Cancer Institute (NCI) glioblastoma multiforme is considered as the most aggressive form of brain cancer with 15.4% of all primary brain tumours and about 60% 75% of all astrocytoma) driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs under clinical trials like CDX-110 (manufactured by Celldex Therapeutics) (Phase 3) and DCVax (Northwest Biotherapeutics) (Phase 3) expected to fuel growth of the market. Rising product approvals from U.S. Food and Drug Administration (FDA) also expected to drive revenue of market. For instance, in March 2005, U.S. Food and Drug Administration (FDA) approved temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment.
North America dominates the glioblastoma multiforme treatment market followed by Europe and Asia-Pacific North American region growth is attributed to an increase in the prevalence of glioblastoma multiforme disease (According to Centres for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumours of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence), investments in research and development, and increasing CNS cancers in the ageing population. Companies betting heavily on research activities due to a lack of drugs to treat glioblastoma multiforme in the market. Similarly, the National Brain Tumour Society, the Brain Tumour Foundation of Canada, and the American Brain Tumour Association are the health organizations engaged in raising awareness about glioblastoma multiforme leads to the growth of the glioblastoma multiforme treatment market over the forecast period.
Europe glioblastoma multiforme treatment market revenue growth is driven by an increase in the geriatric population, a change in lifestyle and an increase in research and development activities by various pharmaceutical companies.
Asia-Pacific is expected to be the fastest-growing market over the forecast period as a result of improving healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment. Furthermore, extensive use of genomic profiling in bioinformatics technology by the research and development firms in the Asia-Pacific region is expected to drive the treatment market for nervous carcinoma by discovering new drug targets.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2.85 billion |
|
Market CAGR |
9.9% |
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The global glioblastoma multiforme treatment market size was valued at US$ 2.85 billion in 2023 and is projected to grow at a CAGR of 9.9% from 2024 to 2030.
The glioblastoma multiforme treatment market key players are: Merck & Co Teva Pharmaceutical Industries Arbor Pharmaceuticals Sun Pharmaceutical Industries F. Hoffmann-Le Roche Abbvie Celldex Therapeutics Exellixis Bristol-Myers Squibb AstraZeneca GlaxoSmithKline CANbridge Life Sciences Apogenix Pfizer Vascular Biogenics
The glioblastoma multiforme treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive summary |
| 2. Global Glioblastoma Multiforme Treatment Market Introduction |
| 2.1. Global Glioblastoma Multiforme Treatment Market Taxonomy |
| 2.2. Global Glioblastoma Multiforme Treatment Market Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Distribution Channel |
| 3. Global Glioblastoma Multiforme Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Glioblastoma Multiforme Treatment Market Dynamics Factors Impact Analysis |
| 3.6. Global Glioblastoma Multiforme Treatment Market Regulations |
| 3.6.1. U.S |
| 3.6.2. Europe |
| 3.6.3. Japan |
| 3.6.4. China |
| 3.7. Global Glioblastoma Multiforme Treatment Market Product Innovations |
| 4. Global Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Oppurtunity Analysis |
| 5. Global Glioblastoma Multiforme Treatment Market, By Drug Type, 2019 - 2023 and Forecast, 2024 - 2030 |
| 5.1. Temozolomide |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Bevacozumab |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Carmustine |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Radiosensitizers |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Glioblastoma Multiforme Treatment Market Forecast, By Distribution Channel , 2019 - 2023 and Forecast, 2024 - 2030 |
| 6.1. Retail Pharmacies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Hospital Pharmacies |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Glioblastoma Multiforme Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Class, Distribution Channel and Region, 2024 - 2030 |
| 8. North America Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 8.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Temozolomide |
| 8.1.2. Bevacozumab |
| 8.1.3. carmustine |
| 8.1.4. Radiosensitizers |
| 8.1.5. Others |
| 8.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Retail Pharmacies |
| 8.2.2. Hospital Pharmacies |
| 8.2.3. Online Pharmacies |
| 8.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel, and Country, 2024 - 2030 |
| 8.5. North America Glioblastoma Multiforme Treatment Market Dynamics Trends |
| 9. Europe Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 9.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Temozolomide |
| 9.1.2. Bevacozumab |
| 9.1.3. carmustine |
| 9.1.4. Radiosensitizers |
| 9.1.5. Others |
| 9.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Retail Pharmacies |
| 9.2.2. Hospital Pharmacies |
| 9.2.3. Online Pharmacies |
| 9.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Poland |
| 9.3.8. Rest of Europe |
| 9.4. Europe Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030 |
| 9.5. Europe Glioblastoma Multiforme Treatment Market Dynamics Trends |
| 10. Asia-Pacific Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 10.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Temozolomide |
| 10.1.2. Bevacozumab |
| 10.1.3. carmustine |
| 10.1.4. Radiosensitizers |
| 10.1.5. Others |
| 10.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Retail Pharmacies |
| 10.2.2. Hospital Pharmacies |
| 10.2.3. Online Pharmacies |
| 10.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030 |
| 10.5. Europe Glioblastoma Multiforme Treatment Market Dynamics Trends |
| 11. Latin America Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 11.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Temozolomide |
| 11.1.2. Bevacozumab |
| 11.1.3. carmustine |
| 11.1.4. Radiosensitizers |
| 11.1.5. Others |
| 11.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Retail Pharmacies |
| 11.2.2. Hospital Pharmacies |
| 11.2.3. Online Pharmacies |
| 11.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Venezuela |
| 11.3.5. Rest of Latin America |
| 11.4. Latin America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030 |
| 11.5. Latin America Glioblastoma Multiforme Treatment Market Dynamics Trends |
| 12. Middle East and Africa Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 12.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Temozolomide |
| 12.1.2. Bevacozumab |
| 12.1.3. carmustine |
| 12.1.4. Radiosensitizers |
| 12.1.5. Others |
| 12.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Retail Pharmacies |
| 12.2.2. Hospital Pharmacies |
| 12.2.3. Online Pharmacies |
| 12.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index By Drug Analysis, Distribution Channel and Country, 2024 - 2030 |
| 12.5. MEA Glioblastoma Multiforme Treatment Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Pfizer, Inc. (U.S) |
| 13.2.2. Allergan Inc. (Ireland) |
| 13.2.3. Boehringer Ingelheim GmbH (Germany) |
| 13.2.4. CIBA Vision Ophthalmics (U.S) |
| 13.2.5. Sanofi (France) |
| 13.2.6. Novartis AG (Switzerland) |
| 13.2.7. Bausch & Lomb Inc. (Valeant) (Canada) |
| 13.2.8. Merck & Co., Inc. (U.S) |
| 13.2.9. Santen Pharmaceuticals Co. Ltd.(Japan) |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.